HYDROGEL SPACER FOR USE IN RADIOTHERAPY TREATMENT OF PROSTATE CANCER

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Medical Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as “Description” defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as “Criteria” defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Medical Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Medical Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

Description:
Hydrogel is a liquid that is injected through the perineum under transrectal ultrasound. The spacer is placed using a small needle, which delivers the liquid hydrogel that solidifies, and creates a physical barrier between the prostate and the rectum thus shielding the anterior rectum from radiation directed at the prostate gland. The solidified hydrogel stays in place around 3 months, after which it is reabsorbed into the body.
HYDROGEL SPACER FOR USE IN RADIOTHERAPY TREATMENT OF PROSTATE CANCER (cont.)

Criteria:

- Hydrogel spacer for use in the radiotherapy treatment of prostate cancer is considered *experimental or investigational* based upon:
  
  1. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and
  2. Insufficient evidence to support improvement of the net health outcome, and
  3. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, and
  4. Insufficient evidence to support improvement outside the investigational setting.

These devices include, *but are not limited to*:

- SpaceOAR®

Resources:

Literature reviewed 09/13/16. We do not include marketing materials, poster boards and non-published literature in our review.


HYDROGEL SPACER FOR USE IN RADIOThERAPY TREATMENT OF PROSTATE CANCER  (cont.)

Resources: (cont.)

